Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Stockholders Equity of $53.52 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -7.1% in Stockholders Equity from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$5.85 million | Q4 2013: -$4.93 million | Q2 2014: -$84.45 million | Q3 2014: -$55.36 million | Q4 2014: -$30.54 million | Q2 2015: -$15.32 million | Q3 2015: -$20.36 million | Q4 2015: -$60.50 million | Q2 2016: -$30.89 million | Q3 2016: $22.48 million | Q4 2016: $26.05 million | Q2 2017: $3.78 million | Q3 2017: $6.19 million | Q4 2017: $5.99 million | Q2 2018: $3.09 million | Q3 2018: $1.77 million | Q4 2018: -$264.6 thousand | Q1 2019: -$2.51 million | Q2 2019: -$1.86 million | Q3 2019: -$3.06 million | Q4 2019: $9.08 million | Q2 2020: $11.79 million | Q3 2020: $14.62 million | Q4 2020: $16.63 million | Q2 2021: $18.70 million | Q3 2021: $20.50 million | Q4 2021: $22.79 million | Q2 2022: $25.53 million | Q3 2022: $27.19 million | Q4 2022: $30.17 million | Q2 2023: $30.12 million | Q3 2023: $45.09 million | Q4 2023: $46.41 million | Q1 2024: $57.58 million | Q2 2024: $58.25 million | Q3 2024: $47.27 million | Q4 2024: $36.45 million | Q1 2025: $53.52 million | Q2 2025: $47.68 million | Q3 2025: $61.58 million | Q4 2025: $80.31 million.
- Over the full 16 years of available data (2010 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Stockholders Equity has grown by 605.0%.
- Historical annual values: Fiscal year 2025: $53.52 million | Fiscal year 2024: $57.58 million | Fiscal year 2023: $28.96 million | Fiscal year 2022: $25.22 million | Fiscal year 2021: $16.15 million | Fiscal year 2020: $10.66 million | Fiscal year 2019: -$2.51 million | Fiscal year 2018: $4.57 million | Fiscal year 2017: $25.66 million | Fiscal year 2016: -$33.12 million | Fiscal year 2015: -$34.73 million | Fiscal year 2014: -$81.20 million | Fiscal year 2013: -$8.67 million | Fiscal year 2012: -$14.98 million | Fiscal year 2011: -$17.87 million | Fiscal year 2010: -$10.60 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: